Why Is Anuh Pharma Share Price Falling: Key Reasons and Investor Analysis 2026

The Anuh Pharma share price falling trend has emerged as a key investor concern in 2026. Anuh Pharma share price falling by approximately 30 percent from its 52 week high of Rs 115 to current levels around Rs 80 has raised questions about whether this correction is temporary or reflects deeper pressure. Anuh Pharma (NSE: ANUHPHR), operating in the Active Pharmaceutical Ingredients space, has seen sustained selling pressure since mid 2025. Understanding the Anuh Pharma share price falling dynamic requires a clear look at both company specific headwinds and the broader macroeconomic forces at work. This article covers every key reason behind the Anuh Pharma share price falling, the financial picture, the technical signals, and the recovery catalysts to watch in 2026.

Click Here – Get Free Investment Predictions

About Anuh Pharma

Anuh Pharma (NSE: ANUHPHR) is a listed company in the Active Pharmaceutical Ingredients segment. Leading API manufacturer. Products include macrolides, antibiotics and anti-TB drugs. Part of SK Group. Incorporated 1960. The stock is currently trading at approximately Rs 80, representing a decline of approximately 30 percent from its 52 week high of Rs 115. The 52 week low for Anuh Pharma is Rs 67. The Anuh Pharma share price falling trend reflects a combination of sector headwinds and company specific pressures that investors need to understand before taking any position decisions.

Parameter	Value
NSE Ticker	ANUHPHR
Sector	Active Pharmaceutical Ingredients
CMP (April-May 2026)	Rs 80
52 Week High	Rs 115
52 Week Low	Rs 67
Decline from 52W High	Approximately 30 percent
Market Cap	Rs 823 crore (approx)
Trailing P/E	Approximately 20x

Why Is Anuh Pharma Share Price Falling: Key Reasons

The Anuh Pharma share price falling is being driven by multiple concurrent pressures. Here are the six primary reasons behind the Anuh Pharma share price falling in 2026.

1. Broad Market Correction and FII Selling Pressure

The dominant external driver behind the Anuh Pharma share price falling is the sustained FII selling wave that swept Indian equities from late 2024 through April 2026. The US reciprocal tariff announcement in April 2026 imposing a 26 percent levy on Indian goods triggered a broad risk off selloff. Anuh Pharma fell alongside the broad market correction as institutional investors reduced India allocations. The Anuh Pharma share price falling by 30 percent from its peak reflects the combination of macro-level FII selling and company specific headwinds operating simultaneously in 2026.

2. Sector-Specific Headwinds in Active Pharmaceutical Ingredients

Beyond the broad market decline, the Active Pharmaceutical Ingredients sector has faced its own challenges in FY26. Analyst earnings estimates for the Active Pharmaceutical Ingredients space have been revised downward across the peer group as input costs, competitive pricing pressures, and demand moderation weighed on the sector outlook. When sector level expectations decline simultaneously, institutional investors reduce overall sector exposure, leading to uniform price declines. The Anuh Pharma share price falling trend is in part a function of this broader sector derating that has continued through early 2026.

3. Earnings Growth Deceleration and Margin Compression

A significant company specific driver behind the Anuh Pharma share price falling is the deceleration in earnings growth relative to the elevated expectations priced into the stock at its 52 week high of Rs 115. Revenue and profitability metrics have come under pressure from input cost inflation, competitive pricing constraints, and higher operating expenditure. The market, which had priced in sustained growth at the 52 week high, is now recalibrating to a more moderate earnings trajectory. This earnings reset is a core driver of the Anuh Pharma share price falling below analyst targets.

4. Valuation De-Rating from Peak Multiples

At its 52 week high of Rs 115, Anuh Pharma was trading at valuations above its historical average. As actual results have come in below peak expectations and sector sentiment has turned cautious, the market has applied lower multiples to Anuh Pharma earnings. This valuation de-rating is one of the core mechanisms behind the Anuh Pharma share price falling from Rs 115 to the current Rs 80. Multiple compression combined with earnings deceleration explains the full magnitude of the 30 percent correction in the Anuh Pharma share price falling phase.

5. Small and Mid Cap Liquidity Squeeze

With a market capitalisation of approximately Rs 823 crore, Anuh Pharma is exposed to the liquidity dynamics of the small and mid cap segment, which experienced one of its sharpest liquidity squeezes in FY25-26. When domestic mutual funds face redemption pressure and retail investors turn risk averse, smaller companies bear disproportionate selling pressure. The Anuh Pharma share price falling has been amplified by this small cap liquidity dynamic where thinner order books convert moderate selling into outsized price declines.

6. Global Macroeconomic Uncertainty and Tariff Headwinds

India’s equity market in FY26 faced an unusually concentrated set of macro headwinds including global tariff wars, crude oil price volatility, currency pressure and concerns about the pace of domestic earnings recovery. The Anuh Pharma share price falling trend has been reinforced by this macro overhang that keeps institutional buyers cautious even when individual company fundamentals do not fully justify the magnitude of the decline. This macro uncertainty is likely to persist until global trade tensions resolve and FII flows return sustainably to Indian equities.

Financial Performance Analysis of Anuh Pharma

The key financial metrics driving the Anuh Pharma share price falling narrative are visible in both recent quarterly trends and the valuation de-rating. The stock has fallen 30 percent from its 52 week high of Rs 115 to the current Rs 80, reflecting both earnings pressure and multiple compression. The market cap has contracted to approximately Rs 823 crore. Investors tracking the Anuh Pharma share price falling should monitor the upcoming Q4 FY26 results and management commentary on the margin and revenue recovery trajectory as the primary near-term catalyst for any stabilisation.

Key Metric	Current Level	52 Week Peak	Trend
Share Price	Rs 80	Rs 115	Down 30 percent
Market Cap (Rs Cr)	Rs 823 crore	Higher at 52W peak	Compressed with price
Trailing P/E	Approximately 20x	Higher at 52W high	Multiple compressed
52 Week Range	Rs 67 to Rs 115

Screen the best stocks on the Univest Screener.

Technical Signals What the Charts Are Saying

On the technical charts, the Anuh Pharma share price falling pattern is confirmed by multiple indicators. The stock is trading at approximately Rs 80, below its 50 day, 100 day, and 200 day simple moving averages, all of which are sloping downward. Since its 52 week high of Rs 115, Anuh Pharma has formed a clear pattern of lower highs and lower lows. Key support for the Anuh Pharma share price falling trend is at the 52 week low of Rs 67. Overhead resistance is at the Rs 115 zone where investors who bought near the peak create selling pressure on any recovery attempt. The RSI has oscillated in oversold territory on multiple occasions during the Anuh Pharma share price falling phase, indicating continued distribution and weak near term buying conviction.

Can Anuh Pharma Share Price Recover

Despite the headwinds currently driving the Anuh Pharma share price falling, there are genuine recovery catalysts for long term investors to track. First, any positive inflection in the Active Pharmaceutical Ingredients sector driven by improved macro conditions or policy support could trigger a sharp re-rating for Anuh Pharma. Second, a quarterly earnings result that beats the now reduced analyst expectations could catalyse a short covering rally from oversold levels. Third, a broad recovery in Indian small and mid cap market sentiment as FII flows normalise post the April 2026 tariff shock would lift Anuh Pharma along with the broader peer group.

The contrarian view is that at Rs 80, a significant portion of the bad news driving the Anuh Pharma share price falling is already priced in. The stock is down 30 percent from its peak and the valuation has compressed meaningfully, creating a potentially attractive entry point for patient investors with a 2 to 3 year horizon willing to look through the near term macro uncertainty.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion

The Anuh Pharma share price falling by approximately 30 percent from its 52 week high of Rs 115 to the current Rs 80 reflects a convergence of broad market headwinds, sector pressures in the Active Pharmaceutical Ingredients space, earnings deceleration, FII selling, and valuation de-rating from peak multiples. The Anuh Pharma share price falling trend will require a clear reversal in quarterly financial momentum and improved macro sentiment to arrest sustainably. Investors monitoring the Anuh Pharma share price falling should closely watch upcoming quarterly results, management commentary on growth and margin recovery, and any shifts in FII ownership.

This article is for informational purposes only. Please conduct your own research and consult a SEBI registered financial advisor before making any investment decisions. Investment in the share market is subject to market risk. SEBI Registration No. INH000013776.

Frequently Asked Questions

Why is Anuh Pharma share price falling in 2026?

The Anuh Pharma share price falling in 2026 is driven by broad market weakness from FII selling triggered by the US tariff announcement in April 2026, sector specific headwinds in the Active Pharmaceutical Ingredients space, earnings growth deceleration, valuation de-rating from peak P/E multiples, and small and mid cap segment liquidity headwinds. The Anuh Pharma share price falling totals approximately 30 percent from the 52 week high of Rs 115 to the current Rs 80.

What is the 52 week high and low of Anuh Pharma?

The 52 week high of Anuh Pharma is Rs 115 and the 52 week low is Rs 67. The current price of approximately Rs 80 represents a decline of about 30 percent from the 52 week high, classifying the Anuh Pharma share price falling as a significant correction that requires careful investor analysis before any fresh position is taken.

Should I buy Anuh Pharma shares at current levels?

Whether to buy Anuh Pharma at Rs 80 during the Anuh Pharma share price falling phase depends on your investment horizon, risk appetite, and your view on the company’s fundamental recovery. The stock has fallen 30 percent from its peak, improving risk reward for patient investors with a 2 to 3 year view. However, near term volatility from the Anuh Pharma share price falling trend may persist. Always consult a SEBI registered financial advisor before making any investment decision.

What is the latest news affecting Anuh Pharma stock?

Recent developments adding to the Anuh Pharma share price falling trend include the US 26 percent reciprocal tariff announcement that triggered FII selling, quarterly earnings showing pressure on margins and revenue growth, and sector level analyst estimate revisions across the Active Pharmaceutical Ingredients space. Track the latest news and live data on Anuh Pharma using the Univest Screener and research platform.

What are the recovery triggers for Anuh Pharma?

Key catalysts that could reverse the Anuh Pharma share price falling trend include a quarterly earnings result that beats reduced analyst expectations, reversal of FII selling as global macro conditions improve post the tariff shock, positive sector re-rating in the Active Pharmaceutical Ingredients space, and a broader small and mid cap market recovery in India. Any of these catalysts could arrest the Anuh Pharma share price falling and trigger a sharp recovery from current levels.

What are the key downside risks to Anuh Pharma stock?

The key risks that could extend the Anuh Pharma share price falling phase include continued earnings estimate downgrades, further FII selling if global risk appetite remains negative, unexpected regulatory or competitive developments in the Active Pharmaceutical Ingredients sector, and a deeper correction in the broader Indian small and mid cap equity segment. If these risks materialise together, the Anuh Pharma share price falling trend could test the 52 week low support of Rs 67.